Due: July 17, 2026
The Rapid Response Partnership Vehicle (RRPV) is issuing this Request for Information (RFI) to better understand the research, development, and product landscape of current and next-generation high-performance immunoassay technologies suitable for antigen testing in near-patient settings. While conventional antigen-based immunoassays offer speed, ease of use, and low cost, they remain limited by lower analytical sensitivity and limited multiplexing capability compared to nucleic acid amplification tests (NAATs), limiting their clinical utility, particularly for early infections and syndromic panels.
This RFI seeks to understand both currently available systems and emerging technologies, including integrated platforms and enabling components, that can bring ultra-sensitive performance into smaller, faster, more deployable, and ideally multiplexed platforms or formats.
Responding to this opportunity requires membership in the Rapid Response Partnership Vehicle (RRPV). This Consortium releases numerous solicitations throughout the year, so even if this opportunity may not end up being right for you, we strongly encourage you to join, so you are ready for the next opportunity.
Complete the form below and a program representative will reach out to you shortly to support you through the process.